Torrey et al. proved that targeting TNFR2 could be an effective treatment as TNFR2 antagonistic antibodies inhibit proliferation of both cancer cells and tumour-infiltrated Tregs while inducing the expansion of Teffs [108]. The gene discussed is TNFRSF1B; the disease is neoplasm.